The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020
Overview
Authors
Affiliations
The first vaccines for prevention of coronavirus disease 2019 (COVID-19) in the United States were authorized for emergency use by the Food and Drug Administration (FDA) (1) and recommended by the Advisory Committee on Immunization Practices (ACIP) in December 2020.* However, demand for COVID-19 vaccines is expected to exceed supply during the first months of the national COVID-19 vaccination program. ACIP advises CDC on population groups and circumstances for vaccine use. On December 1, ACIP recommended that 1) health care personnel and 2) residents of long-term care facilities be offered COVID-19 vaccination first, in Phase 1a of the vaccination program (2). On December 20, 2020, ACIP recommended that in Phase 1b, vaccine should be offered to persons aged ≥75 years and frontline essential workers (non-health care workers), and that in Phase 1c, persons aged 65-74 years, persons aged 16-64 years with high-risk medical conditions, and essential workers not recommended for vaccination in Phase 1b should be offered vaccine.** These recommendations for phased allocation provide guidance for federal, state, and local jurisdictions while vaccine supply is limited. In its deliberations, ACIP considered scientific evidence regarding COVID-19 epidemiology, ethical principles, and vaccination program implementation considerations. ACIP's recommendations for COVID-19 vaccine allocation are interim and might be updated based on changes in conditions of FDA Emergency Use Authorization, FDA authorization for new COVID-19 vaccines, changes in vaccine supply, or changes in COVID-19 epidemiology.
Kern-Allely S, Cash McGinley H, Tippins A, Apaisam C, Basilius M, Leon Guerrero M BMJ Public Health. 2025; 1(1):e000330.
PMID: 40017895 PMC: 11812725. DOI: 10.1136/bmjph-2023-000330.
Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan.
Priyambodo S, Kuo K, Weng K, Liu S, Syu G, Kuo H Ann Med. 2024; 57(1):2442533.
PMID: 39711320 PMC: 11703416. DOI: 10.1080/07853890.2024.2442533.
SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review.
Rustagi V, Gupta S, Talwar C, Singh A, Xiao Z, Jamwal R Immunol Res. 2024; 73(1):17.
PMID: 39692912 DOI: 10.1007/s12026-024-09553-x.
Koizumi N, Hirai T, Kano J, Sato A, Suzuki Y, Sasaki A Int J Mol Sci. 2024; 25(19).
PMID: 39409008 PMC: 11476472. DOI: 10.3390/ijms251910679.
Havelka E, Sanfilippo J, Juneau P, Sherman G, Cooper D, Leggio L Alcohol Alcohol. 2024; 59(6).
PMID: 39371015 PMC: 11456869. DOI: 10.1093/alcalc/agae057.